ipamorelin (NNC 26-0161): the selective growth hormone secretagogue

ipamorelin (development code NNC 26-0161) is a synthetic pentapeptide developed by Novo Nordisk in the mid-1990s that selectively agonizes the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor) on pituitary somatotrophs. its defining pharmacological property is the ability to produce dose-dependent, pulsatile GH release without measurable elevation of ACTH, cortisol, or prolactin -- a selectivity profile that the older GHRPs (GHRP-6, GHRP-2) could not achieve. it has never been approved by any regulator, the only published Phase II efficacy trial was negative, and in October 2024 the FDA's Pharmacy Compounding Advisory Committee voted against allowing it in 503A compounding.

what is ipamorelin and how was it designed?

ipamorelin is a five-amino-acid peptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. its design goal, established by a Novo Nordisk medicinal-chemistry team in Malov, Denmark in the mid-1990s, was to create a GH-secretagogue that drove GH release at potency comparable to GHRP-6 but without the ACTH, cortisol, and prolactin elevation that made the earlier GHRPs problematic as candidate therapeutics.

the critical design change was replacing the N-terminal histidine of the GHRP-1 scaffold with alpha-aminoisobutyric acid (Aib), a conformationally restricted non-natural amino acid that blocks aminopeptidase cleavage at the N-terminus and biases the backbone into a helical turn. the sequence also incorporates two D-amino acids (D-2-naphthylalanine and D-phenylalanine), which contribute protease resistance, and a C-terminal lysine amide, which blocks carboxypeptidase degradation. the result was published as ipamorelin by Raun et al. in the European Journal of Endocrinology in 1998 [1]. the paper's headline finding -- that ipamorelin released GH at potency equivalent to GHRP-6 with no statistically significant ACTH, cortisol, FSH, LH, TSH, or prolactin elevation even at 200-fold the GH ED50 -- has held across two decades of subsequent literature and is the entire reason ipamorelin has remained in scientific conversation despite never reaching the market.

how does it work?

ipamorelin is a full agonist at GHS-R1a, the Gq-coupled GPCR expressed on pituitary somatotrophs that is also the receptor for endogenous ghrelin. activation triggers phospholipase C, which raises intracellular calcium, which drives exocytotic release of GH granules in a discrete, time-locked pulse. the selectivity for GH over ACTH and prolactin release is believed to reflect biased agonism at GHS-R1a -- ipamorelin engages a receptor conformation that couples efficiently to the somatotroph GH-release machinery but couples weakly to the arcuate-nucleus and corticotroph signaling branches that drive the unwanted hormonal effects.

GHS-R1a activation produces a pulsatile GH signal that mimics the natural nocturnal slow-wave-sleep GH pulse, rather than the continuous GH elevation associated with exogenous growth hormone injection. this pulsatility matters because tissues read GH pulse patterns, not time-averaged GH concentrations: pulsatile GH drives sex-specific liver gene expression programs through STAT5b kinetics that continuous exposure cannot replicate. GHS-R1a internalizes and desensitizes after agonist exposure and recovers full responsiveness within approximately 3-4 hours, which is why community protocols use intermittent rather than continuous dosing.

the most clinically relevant mechanistic concept for ipamorelin is its synergy with GHRH-axis agonists. GH release from somatotrophs is governed by two inputs: hypothalamic GHRH (stimulatory, via GHRHR, the cAMP-PKA pathway) and somatostatin (inhibitory). ipamorelin acts on a third, parallel pathway that potentiates GHRH signaling and partially antagonizes somatostatin. co-administration of a GHRH analog (sermorelin, CJC-1295, tesamorelin) with ipamorelin produces synergistic GH pulses markedly larger than either agonist alone, a principle demonstrated in healthy adults by Bowers et al. in the Journal of Clinical Endocrinology and Metabolism in 1990 and confirmed repeatedly since [2]. this synergy is the mechanistic rationale for the CJC-1295 + ipamorelin community stack.

what do the human trials show?

the clinical evidence base for ipamorelin consists of one rigorous Phase I pharmacokinetics study and one Phase II efficacy trial. the Phase I showed clean, dose-proportional GH release. the Phase II, the only published randomized controlled efficacy trial of ipamorelin in any real indication, was negative. there are no published controlled human trials in body composition, anti-aging, sleep, or any other community-marketed endpoint.

Gobburu et al. 1999 in Pharmaceutical Research (PMID 10496658) remains the single rigorous human pharmacokinetics publication [3]. the study randomized 48 healthy male volunteers to five dose levels of 15-minute IV infusions. findings: dose-proportional pharmacokinetics across a 33-fold range; terminal half-life approximately 2 hours; GH Cmax of 20-223 mU/L, dose-dependent; GH return to baseline within approximately 3 hours; no serious adverse events. this study established that ipamorelin does what Raun's preclinical work predicted in healthy humans. what it did not establish -- and what is consistently overstated in community materials -- is any clinical outcome.

the Phase II efficacy trial is Beck et al. 2014 in the International Journal of Colorectal Disease (PMID 25331030) [4]. this was a Helsinn-sponsored multicenter, double-blind, placebo-controlled, randomized proof-of-concept trial (n=114) of IV ipamorelin twice daily versus placebo for up to 7 days in adults undergoing open or laparoscopic bowel resection. primary endpoint: time to first bowel movement and tolerance of solid food. result: ipamorelin was well tolerated but produced no statistically significant difference versus placebo on the primary or key secondary efficacy endpoints. development was discontinued. this is the only Western-standard RCT of ipamorelin ever published in a real clinical efficacy indication, and it was negative. community advocacy has since shifted the marketing target to unmeasured endpoints -- body composition, anti-aging, recovery -- where there is no comparable trial to be negative.

the preclinical evidence in bone is the only scientifically meaningful non-GI dataset. Svensson et al. 2000 in the Journal of Endocrinology (PMID 10828840) reported that 12-week continuous subcutaneous infusion in adult female rats increased tibial and vertebral bone mineral content versus vehicle [5]. a follow-up study showed partial counteraction of glucocorticoid-induced bone-formation marker suppression. these are animal data with no human controlled equivalent; continuous infusion is also not the protocol used in human community practice.

regulatory status in 2026

ipamorelin is not approved by the FDA, EMA, MHRA, TGA, or any national regulator. in October 2024 the FDA's Pharmacy Compounding Advisory Committee voted against adding ipamorelin to the 503A bulks list. it remains prohibited under WADA S2.2.2 for all athletes.

the regulatory history is detailed and worth tracing accurately. Novo Nordisk discontinued ipamorelin development in the early-to-mid 2000s; no internal safety red flag was published, but the underlying development data have never been released. Helsinn acquired rights, ran the Phase II ileus trial, and discontinued after the 2014 negative result. in September 2023, the FDA placed ipamorelin into Category 2 of the interim 503A bulk substances list, effectively banning compounding pending safety and efficacy review. litigation followed (Evexias / Farmakeio v. FDA), and a September 2024 settlement required FDA to submit the disputed peptides to the Pharmacy Compounding Advisory Committee (PCAC) for public review. on October 29, 2024, the PCAC voted against adding ipamorelin (and ipamorelin acetate) to the 503A bulks list [6]. ipamorelin therefore remains ineligible for legal 503A compounding in the United States. any commercially sold product labeled as ipamorelin for human use is the sale of an unapproved new drug under FDCA section 505.

for athletes under WADA jurisdiction, ipamorelin is prohibited at all times under section S2.2.2 (growth hormone secretagogues and their mimetics). the 2026 detection threshold for the GHS class was lowered to 0.1 ng/mL by LC-MS/MS [7].

where ipamorelin fits in the GH-axis landscape

ipamorelin occupies a unique position as the most pharmacologically characterized non-approved GH-axis peptide: it has better selectivity data than the older GHRPs, cleaner Phase I PK than any GHRH analog outside tesamorelin, and a stronger mechanistic rationale for the CJC-1295 combination than any alternative -- but it also has no approved indication, no published controlled human outcome trial in its marketed uses, and an FDA regulatory status that as of October 2024 explicitly blocks the compounding pathway that sustained its grey-market availability.

the honest comparison is with tesamorelin, which acts at the GHRH receptor rather than GHS-R1a, carries FDA approval and Phase 3 RCT evidence for visceral fat reduction in HIV-associated lipodystrophy, and is the benchmark any GH-axis body-composition claim must be measured against. the two are mechanistically complementary -- GHRH-pathway and GHS-R1a-pathway synergy is one of the better-characterized two-receptor interactions in human endocrinology -- but no controlled trial has ever measured a clinical outcome for the tesamorelin + ipamorelin combination. for a broader map of how the GH axis connects to the incretin family that includes semaglutide and tirzepatide, the underlying biology is covered in our free peptides and your body module.